Cargando…

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in the liver. Approximately one-sixth of the NAFLD population progresses to non-alcoholic steatohepat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tillman, Erik J., Rolph, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767990/ https://www.ncbi.nlm.nih.gov/pubmed/33381084 http://dx.doi.org/10.3389/fendo.2020.601290

Ejemplares similares

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
por: Kaufman, Allegra, et al.
Publicado: (2020)

Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
por: Luci, Carmelo, et al.
Publicado: (2020)

Metabolic Effects of FGF-21: Thermoregulation and Beyond
por: Ni, Bin, et al.
Publicado: (2015)

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
por: Tillman, Erik J., et al.
Publicado: (2022)

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
por: Pan, Qi, et al.
Publicado: (2021)

FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
por: Itoh, Nobuyuki
Publicado: (2014)

Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans
por: De Sousa-Coelho, A. L., et al.
Publicado: (2023)

FGF21 and Cardiac Physiopathology
por: Planavila, Anna, et al.
Publicado: (2015)

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
por: Henriksson, Emma, et al.
Publicado: (2020)

Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
por: Aaldijk, Alexandra S., et al.
Publicado: (2023)

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway
por: Liu, Yu, et al.
Publicado: (2021)

Stressed Liver and Muscle Call on Adipocytes with FGF21
por: Luo, Yongde, et al.
Publicado: (2013)

The Hepatokine FGF21 Increases the Human Spermatozoa Motility
por: Bourdon, Guillaume, et al.
Publicado: (2022)

Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21
por: Akbari, Rasoul, et al.
Publicado: (2020)

Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis
por: Hou, Hsuan-Wu, et al.
Publicado: (2022)

The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model
por: Spann, Redin A., et al.
Publicado: (2022)

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
por: Dennis, Andrea, et al.
Publicado: (2021)

Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing
por: Pellegrina, Diogo, et al.
Publicado: (2023)

Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine
por: Fang, Han, et al.
Publicado: (2021)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis
por: Yang, Yoon Mee, et al.
Publicado: (2018)

Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis
por: Lan, Tian, et al.
Publicado: (2022)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

HDAC11, an emerging therapeutic target for metabolic disorders
por: Chen, Huizhen, et al.
Publicado: (2022)

Improved FGF21 Sensitivity and Restored FGF21 Signaling Pathway in High-Fat Diet/Streptozotocin-Induced Diabetic Rats After Duodenal-Jejunal Bypass and Sleeve Gastrectomy
por: Liu, Qiaoran, et al.
Publicado: (2019)

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
por: Kim, Kook Hwan, et al.
Publicado: (2018)

Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD
por: Inagaki, Takeshi
Publicado: (2015)

The roles of FGF21 and GDF15 in mediating the mitochondrial integrated stress response
por: Jena, Jayashree, et al.
Publicado: (2023)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtype: A Case-Control Study
por: Wang, Ning, et al.
Publicado: (2021)

Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
por: Hirsova, Petra, et al.
Publicado: (2021)

Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form
por: Crudele, Lucilla, et al.
Publicado: (2023)

Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity
por: Long, Xiaoxue, et al.
Publicado: (2021)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review
por: Yaqub, Sayma, et al.
Publicado: (2021)

Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway
por: Yue, Si-Ran, et al.
Publicado: (2022)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications
por: Vitale, Giovanni, et al.
Publicado: (2021)

miR‐149 controls non‐alcoholic fatty liver by targeting FGF‐21
por: Xiao, Junjie, et al.
Publicado: (2016)

The Association Between FGF21 and Diabetic Erectile Dysfunction: Evidence from Clinical and Animal Studies
por: Yang, Song, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bm0d7t7arcj9mrpvvusnbud6s1